The estimated Net Worth of Charles W Iii Newhall is at least $16.8 Million dollars as of 16 November 2023. Mr. Newhall owns over 7,457 units of Supernus Pharmaceuticals Inc stock worth over $3,716,826 and over the last 18 years he sold SUPN stock worth over $12,718,113. In addition, he makes $375,953 as Independent Chairman of the Board at Supernus Pharmaceuticals Inc.
Charles has made over 9 trades of the Supernus Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 7,457 units of SUPN stock worth $68,903 on 16 November 2023.
The largest trade he's ever made was buying 4,400,000 units of Supernus Pharmaceuticals Inc stock on 4 May 2012 worth over $22,000,000. On average, Charles trades about 170,795 units every 154 days since 2006. As of 16 November 2023 he still owns at least 119,589 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Newhall stock trades at the bottom of the page.
Charles W. Newhall III serves as Independent Chairman of the Board of the Company. In 1977, Mr. Newhall co-founded NEA, a venture capital firm that focuses on the medical and life sciences and information technology industries, from which he retired effective December 31, 2012. To date, Mr. Newhall has served as a director of over 50 venture-backed companies. In 1986, he founded the Mid-Atlantic Venture Capital Association (MAVA), which now has over 500 venture capital firms that are members, and is one of the most active regional venture associations in the country. He is Chairman Emeritus of MAVA. He has served as an advisor to Greenspring Associates since 2012. Before NEA, Mr. Newhall was a Vice President of T. Rowe Price. He served in Vietnam commanding an independent platoon including an initial reconnaissance of Hamburger Hill. His decorations include the Silver Star, Bronze Star V (1st OLC) and the Purple Heart. He earned an Honors Degree in English from the University of Pennsylvania and an MBA from Harvard Business School. Mr. Newhall's substantial experience with companies in the healthcare sector and his venture capital, financial and business experience qualify him to serve as a director.
As the Independent Chairman of the Board of Supernus Pharmaceuticals Inc, the total compensation of Charles Newhall at Supernus Pharmaceuticals Inc is $375,953. There are 7 executives at Supernus Pharmaceuticals Inc getting paid more, with Jack Khattar having the highest compensation of $8,123,130.
Charles Newhall is 75, he's been the Independent Chairman of the Board of Supernus Pharmaceuticals Inc since 2016. There are 1 older and 15 younger executives at Supernus Pharmaceuticals Inc. The oldest executive at Supernus Pharmaceuticals Inc is John Siebert, 80, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: